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Abstract 
 
Acute Myeloid Leukemia (AML) is a cancer of overproliferative blood cells and is the most 
common type of blood cancer to occur in adults.  AML patients are commonly treated with 
chemotherapeutic approaches. Although chemotherapy drugs are effective at limiting growth of 
leukemia cells, the pathways that they target are common in all proliferating cells and as a 
result, healthy proliferative tissue is also damaged.  Currently, the identification and 
development of therapies that specifically or preferentially impact growth of leukemia cells is in 
high demand. Alisertib (MLN8237), an inhibitor of the mitotic kinase Aurora A is one potential 
drug that is currently being investigated clinically as a co-therapeutic for AML.  AML cells have 
been reported to exhibit high levels of Aurora A and so are hypothesized to be exquisitely 
sensitive to inhibition of this mitotic regulator.  However, the cell biological impact of Aurora A 
inhibition in AML cells has not been investigated, and it is unclear if Aurora A expression levels 
alone may be a good predictor of sensitivity to Alisertib. 
 
Our studies have focused on exploring the molecular effects of Aurora A inhibition, and 
investigating cellular biomarkers, in addition to Aurora A levels, that may predict drug sensitivity 
in AML patients.  Our initial correlative studies in a panel of AML cell lines, does not show a 
clear correlation between Aurora A levels and Alisertib sensitivity.  Instead, our results suggest 
that an increased centriole number confers resistance of AML cells to Alisertib. We will continue 
to define centriole number as a potential biomarker through ongoing approaches that will test 
both the contribution of Aurora A levels and centriole number, both in isolation and in 
combination, on Alisertib sensitivity.  
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1. Introduction  
 
Acute Myeloid Leukemia (AML) is a type of blood cancer that occurs when the bone marrow 
makes abnormal myoblasts, platelets or red blood cells. These abnormal cells continue to 
develop and accumulate within the blood vessels which can result in anemia or easy bleeding. 
According to the American Cancer Society, AML is the most common type of blood cancer to 
occur in adults, and is generally seen in adults above the age of. The percent of individuals that 
will survive five years after AML diagnosis is approximately 27%. Most of the individuals will 
initially experience flu-like symptoms, including fever, sweats or body aches.  According to the 
Seattle Cancer Care Alliance, in order to diagnose AML, several tests are needed, including a 
bone marrow biopsy, complete blood cell counts or tests for genetic abnormalities. Currently, 
chemotherapy is the most common treatment given to AML patients. This treatment is generally 
given in two steps, and the purpose of the treatment is to use chemotherapy drugs to eradicate 
all of the leukemic cells. However, chemotherapeutic approaches do not specifically target 
cancer cells but instead target all proliferating cells and cause side effects that impact the health 
of the patient as stated by the American Cancer Society. Targeted therapies are now being 
pursued, that may exclusively, or preferentially, target cancer cells through the use of an Aurora 
A kinase inhibitor called Alisertib.  
 
Aurora A kinase is part of a family of serine/threonine kinases that are vital in cell cycle 
regulation and mitosis (Fu et al., 2007).  Aurora A kinase’s function is to control mitotic entry, 
and recruit components for centrosome maturation. Aurora A plays a critical role in the 
formation of a bipolar mitotic spindle, which is crucial for the proper separation of the sister 
chromatids to each of the daughter cells (Dutertre et al., 2002). When Aurora A kinase is 
overexpressed, centrosome amplification, cytokinesis inhibition and aneuploidy can result.  
Aurora A kinase has been found to be overexpressed in a variety of cancers, including breast, 
colon, and AML. Its role within the cell, and together with its overexpression profile in a range of 
cancers suggest that Aurora A is a promising drug target.  
 
Previous studies have shown that the inhibition of Aurora A kinase function through depletion or 
inhibition results in mitotic spindle assembly defects (Manfredi, et al., 2011). Loss of Aurora A 
function disrupts mitotic spindle formation and results in spindles with one or multiple spindle 
poles. The Aurora A kinase inhibitor that this paper focuses on is Alisertib (or MLN8237). 
Alisertib has been shown to disrupt the growth of Acute Myeloid Leukemia (AML) cells, and a 
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common phenotype of Alisertib-treated AML cells is a monopolar spindle pole (Moore, A.S, et 
al, 2010).    However, not all AML cells exhibit the same degree of Aurora A amplification, or 
spindle morphology defects and it remains unclear in which contexts Aurora A inhibition may 
have the greatest therapeutic value. In this Major Qualifying Project we aim to define the cellular 
implications of Aurora A kinase inhibition with Alisertib, and to investigate cellular biomarkers 
that predict drug response. In addition biomarkers that could suggest Alisertib would be more or 
less effective are considered. Lastly, this project explores the possibility that centriole number, 
independent of Aurora A level indicates the responsiveness of an AML cell to Alisertib.   
 
  
 
 
 | 5 P a g e
 
2. Background 
2.1 Acute Myeloid Leukemia (AML) 
The National Cancer Institute defines hematopoietic stem cells, also known as blood stem cells, 
as immature cells that have the ability to self-renew and to differentiate into any type of blood 
cell. These cells are generally identified in the bone marrow, the soft, sponge-like tissue in the 
center of bones. Hematopoietic stem cells first differentiate into blood cells of two different 
lineages, the lymphoid and myeloid, which give rise to many other types of cells. The lymphoid 
stem cells further differentiate into T cells, B cells, and natural killer (NK) cells. The myeloid 
lineage gives rise to megakaryocytes, erythrocytes (MegE), as well as granulocytes (Iwaski and 
Akashi, 2007). Mature blood cells have short life-spans, and new blood cells are derived from 
hematopoietic blood cells (Robb, 2007). 
 
According to the Johns Hopkins 
Comprehensive Cancer Center, blood 
cancers usually develop in the bone 
marrow, and it affects both the 
production and function of blood cells. 
Each type of blood cancer is due to 
defects in specific cell lineages. The 
hematopoietic stem cells replace the 
normal blood cells as they age and die. 
However, when an individual has blood 
cancer, this process is corrupted. 
Hematopoietic stem cells may not 
grow or differentiate normally, or the 
immune system will attack normal 
tissue. According to the American 
Society of Hematology, in all three 
different types of blood cancers - lymphoma, myeloma, and leukemia - the development of 
blood cells is hindered by the uncontrolled growth of a progenitor.  
 
 
The Mayo Clinic defines acute myeloid leukemia (AML), or acute myelogenous leukemia, as a 
type of blood cancer that occurs in bone marrow. According to the National Cancer Institute, 
Figure 1. Differentiation of Hematopoietic Stem Cells  
Blood stem cells can differentiate into two lineages of blood 
cells: Myeloid and Lymphoid. Each lineage is responsible for 
the production of different blood cell types 
 
Retrieved from: Winslow, Terese. National Cancer Institute. 2007 
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AML progresses rapidly and only affects the myeloid lineage of cells, therefore affecting the 
development of red blood cells, platelets and myeloblasts.  These abnormal cells accumulate in 
the blood vessels and take the space of healthy blood cells. This might lead to anemia and easy 
bleeding.  
2.1.1 Prevalence, Risk Factors and Symptoms 
 
According to the World Health Organization, the incidence of AML worldwide in 2012 was 
351,965 people.  AML commonly occurs at older ages, with an average of 67 years old, and the 
lifetime risk for its occurrence is between 0.5 and 1%. According to the National Cancer 
Institute, the average 5-year survival rate for people with AML is 27%. 
 
During the early stages of AML, patients will experience symptoms similar to the flu including 
fevers, sweats and body aches. The symptoms can vary based on the deficiency of various 
blood cell types. For example, patients will low white blood cells will suffer from bacterial or viral 
infections, and have occurrences of mouth inflammation or sores. To determine if the patient 
has AML, several tests have to be completed to accurately diagnose the patient. According to 
the Seattle Cancer Care Alliance, these can include bone marrow biopsies, complete blood 
counts, and a polymerase chain reaction to test for the presence of a certain chromosomal 
translocation. Other tests can be used to detect genetic abnormalities, like examining the FLT3 
gene for example. The FLT3 gene, when abnormal, has been correlated with poor prognosis in 
AML patients. In addition to the FLT3 gene, Aurora A kinase has been observed to be 
overexpressed in AML compared with normal hematopoietic stem cells (Kim et al., 2012).  
 
To date, a high risk factor associated with the development of AML is smoking. Substances 
present in tobacco do not only affect the cells that are in direct contact with them, such as the 
lung cells, but it also can affect the cells in the bloodstream, since the smoke diffuses from the 
lungs to the blood vessels (Lichtman, 2007). There are other risk factors that could increase the 
probability of AML development, including prolonged exposure to specific chemotherapy drugs 
such as alkylating agents, platinum agents, and topoisomerases II inhibitors. These can be used 
as treatments for other cancers. In addition, having blood diseases (i.e polycythemia vera, and 
idiopathic myelofibrosis) and genetic syndromes (i.e. down syndrome and fanconi anemia) have 
been linked to an increased risk of developing AML, especially when chemotherapy drugs have 
been used, as reported in the American Cancer Society. Although a few of the patients present 
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some of these risks factors, their presence alone is not sufficient to cause cancer. AML 
commonly develops after an accumulation of mutations in DNA over time, which can happen 
because of unknown reasons. While translocations are the most common chromosomal 
changes found in AML, many others can also occur, such as deletions, inversion, insertions or 
duplications.  
2.1.2 Current Treatments 
Currently, the most common type of treatment for AML is chemotherapy, and this can be 
followed by a stem cell transplant. The chemotherapy is conducted in two steps: induction and 
consolidation. Induction is the first phase, and aims to eliminate leukemic cells from the blood, 
get rid of all signs of disease for an extended time (also known as remission) and to increase 
the healthy blood count to within a normal range. Generally, doctors will use two or more 
chemotherapy drugs to treat AML, as each individual drug utilizes different methods to destroy 
the cancer cells. Therefore, combining drugs can strengthen the treatment’s effectiveness.  The 
second step, consolidation, is conducted after the patient has recovered from induction. The 
second phase is targeted at killing the small population of leukemia cells that may remain after 
induction. According to the Leukemia & Lymphoma Society, without consolidation, or 
“postremission therapy”, the AML has a higher probability of returning.  
 
Common chemotherapy drugs include cytarabine or anthracycline drugs. Cytarabine, once 
phosphorylated and is incorporated into DNA, will block DNA elongation by inhibiting DNA 
polymerase, and results in a decrease of DNA replication and repair (Fitzakerley, 2015). 
Anthracycline drugs primarily act through intercalation. Intercalation inserts an aromatic ring 
between DNA base pairs, compromises replication, and results in cytotoxicity (Barton et al, 
1991).  However, both of these chemotherapies can also harm other types of proliferative cells. 
According to the American Cancer Society, chemotherapy drugs can result in side effects 
including nausea, hair loss, mouth sores, fatigue, increased bruising and risk of infections. 
 
Although the patient survival has increased over the years, the current treatments are not 
effective enough in patients older than 60 in which AML is more prevalent. Because of this, 
there is a need for the discovery of new targets for the development of new effective 
therapeutics.  
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2.2 Acute Myeloid Leukemia and Aurora A Kinase 
 
In normal human cells, the cell cycle consists of four phases: S phase (chromosomal 
duplication), M phase (chromosomal separation) and two Gap phases (G1 and G2) that 
separate both S and M phases (see Figure 2)(van den Heuvel, 2005). The M phase consists of 
four stages: prophase, metaphase, anaphase, and telophase (O'Connor, 2008). During 
prophase, the chromosomes begin to condense, the nuclear envelope starts to break down,  
and the mitotic spindle begins to form. Following prophase, the cell proceeds to pro-metaphase 
where chromosomes attach to the spindle microtubules and begin to congress towards the 
center of the cell. Once all chromosomes have fully attached to a bipolar spindle and aligned at 
the spindle center, the cell is said to be in metaphase. The microtubules nucleated at the 
centrosomes attach to protein structures known as kinetochores. Attached chromosomes orient 
so that each replicated chromosome is associated with microtubules nucleated from a single 
centrosome/spindle pole. This attachment and alignment satisfies the spindle assembly 
checkpoint and enables the cell to enter anaphase. During this phase, cohesion between 
replicated chromosomes is lost and the sister chromatids are pulled apart and towards different 
cell poles. Following anaphase, nuclear envelopes reform around decondensing chromatin and 
cyotokinesis cleaves the dividing cell into two genetically identical daughters (O'Connor, 2008). 
 
Centrosomes are organelles that organize microtubules and are involved in the process of 
cytokinesis (O’Connor & Adams, 2010). The centrosomes are composed of three parts: two 
centrioles (a mother and a daughter centriole), a matrix that connects the two centrioles, and 
pericentriolar material. As seen in Figure 2, the centrosomes are duplicated during S phase.  
The cell before mitosis contains four centrioles that are organized in two centrosomes.  As the 
cell moves into mitosis, the centrosomes move apart towards opposite sides of the cell, where 
they nucleate and organize the microtubules of the mitotic spindle. After cytokinesis, each of the 
daughter cells contains a single centrosome with two centrioles. 
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2.2.1 Aurora Kinases Function and Regulation 
Aurora kinases are a family of serine/threonine kinases that have been implicated in cell cycle 
control, and are vital during mitosis (Fu et al., 2007). These kinases are enzymes that control 
the functions of many substrates by phosphorylation. There are three members of the Aurora 
kinase family: Aurora A, Aurora B, and Aurora C (Fu et al., 2007). The activity of Aurora kinases 
is closely regulated, as disruption or deregulation of 
these kinases can lead to genetic instability due to 
defects in centrosome function, spindle assembly 
and chromosomal alignment. Aurora A plays a role 
in mitotic spindle assembly through facilitating 
centrosome maturation by recruiting various 
components such as y-tubulin (Fu et al., 2007). 
Aurora B regulates chromatid protein modification 
and separation and also known to play a role in 
cytokinesis. For example, when Aurora B kinase is 
depleted the cell will become polyploid (Fu et al., 
2007). According to the National Center for 
Biotechnology Information, Aurora C has been 
known to play a role in microtubule organization in 
centrosome and spindle function during mitosis by 
forming complexes with Aurora B and centromere 
proteins. In many human cancers, the expression 
and activity of the Aurora kinases is increased, 
suggesting that they may play a role in 
tumorigenesis, and has become the focus of many 
anti-cancer drugs and treatments (Fu et al., 2007).  
 
The cell cycle is primarily regulated by cyclin-dependent kinases, also known as CDKs. CDKs 
are further regulated by phosphorylation, degradation of proteins that inhibit cyclin, and 
degradation of cyclins, among others (van den Heuval, 2005). The mitotic events of the cell 
cycle have other regulatory molecules besides CDKs, such as polo-like kinases, and aurora 
kinases. Aurora A kinase, for example, functions to control mitotic entry, which happens after 
the activation of CDK1 (Figure 3). This control is done indirectly, by interactions with Polo-like 
kinase 1 (Plk-1), a cell cycle kinase that regulates processes such as centrosome maturation, 
Figure 2. Aurora A Kinase and Centrosome 
Separation 
Centrosomes are duplicated during S phase, 
move apart upon mitotic entry where they 
become microtubule nucleating centers that 
make up functional spindle poles 
 
Retrieved from: Dutertre, Stephanie, Simon Descamps, 
and Claude Prigent. "On the Role of Aurora-A in 
Centrosome Function."Nature.com. Macmillan Publishers, 
9 Sept. 2002. Web. 01 Feb. 2017. 
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spindle assembly and chromatin 
cohesion (Bruinsma et al., 2014). Plk-1 is 
located at the centrosomes and mitotic 
spindle. Plk-1 is switched on by 
phosphorylation at residue T210 during 
G2 phase, reaching its maximum activity 
during mitosis, after it is phosphorylated 
at residue T210 (Bruinsma et al., 2014). 
The phosphorylation of this residue is 
done by the Aurora A-Bora complex. The 
phosphorylation of residue T210 causes 
a change in the conformation of Plk-1 that 
provides Aurora A enhanced access to 
residue T210 (Fu, Jiang & Zhang, 2010). 
Inhibition of Aurora A has been shown to 
prevent the activation of Plk-1 and lead to 
the formation of monopolar spindles.  
 
During S phase, Aurora A localizes on 
duplicated centrosomes, and remains 
there until the beginning of G1 during the following cell cycle.  While located on the 
centrosomes, Aurora A has three functions.  First, as shown by experiments performed in 
Xenopus and in Drosophila, Aurora A contributes to centrosome separation.  In these two 
animals, inactivation of Aurora A results in the formation of monopolar spindles, with the 
centrosomes failing to separate (Duterte et al., 2002). The mechanism by which Aurora A 
contributes to centrosome separation is through phosphorylation Eg5, a protein required for 
centrosome separation to occur. A second function of Aurora A at the centrosomes is to ensure 
that centrosome mature after they separate before mitosis. This maturation includes the 
recruitment of proteins, such as y-tubulin and centrosomin, to the centrosome to take part in its 
structure as well as to preserve its functionality during and after mitosis (Duterte et al., 2002). 
.  
Lastly, Aurora A recruits and phosphorylates TACC3 at the centrosome. TACC3 is a protein that 
promotes microtubule stabilization (Lioutas & Vernos, 2013). This interaction contributes to the 
organization and stabilization of microtubules (Fu et al., 2007). 
 
Figure 3. Role of CDK, Aurora A Kinase and Polo-
Kinase 1 
CDK1 activates the Aurora Bora complex, which 
leads to the phosphorylation and activation of PLK1. 
This results in the phosphorylation of residue T210  
 
Retrieved  from:  Fu, J., Jiang, Q. & Zhang, C. (2010) Collaboration 
of Mitotic Kinases in Cell Cycle Control. Nature Education 3(9):82 
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Both the localization and activity of Aurora A is carefully regulated to ensure that it correctly 
functions within the cells. In 
normal cells, Aurora A is down-
regulated through APC/C-Cdh1 
dependent, proteasome-
mediated proteolysis. The 
degradation of Aurora A by 
APC/C-Cdh1 requires a 
destruction box in the C-
terminal region and a motif in 
the N-terminus (D'Assoro et al., 
2016). Aurora A is a major 
contributor to the proper 
segregation of the daughter 
cells during mitosis and 
Deregulation of its localization 
and activity can lead to 
abnormal spindle morphology 
and promote tumorigenesis 
(Duterte et al., 2002).  
2.2.2. Aurora A Kinase Overexpression and Effects in the Cell Cycle 
 
The Aurora A gene is located in the 20q13 chromosome region, and is amplified in many 
cancers including breast, colon and ovarian cancers, leading to the overexpression of Aurora A 
kinase (Duterte et al., 2002). In a large majority of these cancers, the localization of Aurora  A  is 
diffused, being present in other parts of the cell such as the cytoplasm, and not being 
concentrated in the nucleus (Duterte et al., 2002).  
 
Centrioles are duplicated during S phase concurrent DNA replication. The cell, therefore, 
contains four centrioles that are organized into two centrosomes throughout G2 and mitosis. 
Aurora A kinase activity is not observed until the G2 phase, which implies that the kinase activity 
of Aurora A is not needed in order to duplicate the centrioles (Duterte et al., 2002). While the 
activity of Aurora A is not required for centriole amplification, the overexpression of Aurora A 
has been shown to be sufficient for overamplification of centrioles (Meraldi et al., 2002). Recent 
Centrosomes duplicate during S phase, and move apart during 
G2/M phase. Aurora A contributes to centrosome separation  
during G2 phase.  
 
Retrieved from: Wang, Gang, Qing Jiang, and Chuanmao Zhang. "The Role of 
Mitotic Kinases in Coupling the Centrosome Cycle with the Assembly of the Mitotic 
Spindle." Journal of cell science, vol. 127, no. Pt 19, 2014, pp. 4111-
4122doi:10.1242/jcs.151753 
Figure 4. Diagram of Centrosome Duplication and Aurora A localization 
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studies show that cells overexpressing 
Aurora A and containing increased number 
of centrioles also have multiple nuclei, 
suggesting that these cells experience 
abnormal mitosis. Overexpression of Aurora 
A causes cells to form aberrant mitotic 
structures, and defective anaphases 
including the presence of anaphase bridges 
and cytoplasmic connections (Meraldi et al., 
2002). These aberrant anaphase defects 
cause the cells to fail cytokinesis, leading to 
the formation of tetraploid cells. Some cells 
that overexpress Aurora A kinase also 
overexpress Plk1 and Aurora B kinase, 
which have also been shown to cause an 
amplification of centrosomes (Meraldi et al., 
2002). This amplification of centrosomes is 
also correlated with loss or mutation of p53, 
a tumor suppressor that plays a role during 
DNA damage response (Figure 5) 
(Goodsell, 2002). Cells that do not have a 
functional p53 protein have been shown to 
have a higher number of centrosomes when 
Aurora A, Aurora B or Plk1 are 
overexpressed. This could explain why the 
overexpression of Aurora A leads to the 
formation of multiple centrosomes, as p53 
loss would abrogate the checkpoint for 
aberrant mitotic cells, and permit their continued cycling (Meraldi et al., 2002).    
 
 
 
  
      
Errors in DNA replication, mitotic progression, or 
impaired mitotic checkpoints can result in an 
abortive mitotic exit. Cells lacking p53 can bypass 
G1 arrest cell death, and result in centrosome 
amplification 
 
Retrieved from: Meraldi, Patrick, Reiko Honda, and Erich 
A.Nigg. "Aurora‐A Overexpression Reveals Tetraploidization as 
a Major Route to Centrosome Amplification in P53−/− Cells." 
The EMBO Journal. EMBO Press, 15 Feb. 2002. Web. 28 Feb. 
2017 
 
Figure 5. Diagram of Mitotic Errors 
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2.2.3 Aurora A Kinase Inhibition and Implications  
 
Currently, due to the role of Aurora A within the cell 
and its overexpression in many cancers, the effect 
of inhibition of Aurora A is being investigated.   It 
has been observed that Aurora A inhibition can 
lead to mitotic spindle assembly defects, such as 
monopolar spindle poles which activate the spindle 
assembly checkpoint and induce mitotic arrest 
(Bavetsias & Linardopoulos, 2015). Following a 
prolonged mitotic arrest, some cells undergo 
mitotic catastrophe. Other cells that ultimately exit 
mitosis and enter G1 will senesce or apoptose. 
However, not all cancer cells respond similarly to 
Aurora A inhibition and it remains unclear what 
features of a cancer cell may promote the preferred 
mitotic catastrophe or apoptosis, over a G1 arrest. 
There are multiple Aurora A inhibitors in clinical 
trials, including AT9283, PF-03814735, and 
Alisertib (or MLN8237).  
 
First, AT9283 is a heterocyclic molecule that 
inhibits aurora kinases, including both Aurora 
kinase A and B. This inhibitor is used as a therapy 
for many solid tumors and leukemic cancers, as it 
shows a reduction in the proliferative profile of 
leukemic cancers, as well as an induction of 
aneuploidy and apoptosis (Qi et al., 2012).  Second, PF-03814735 is a reversible inhibitor of 
both Aurora kinase A and B, and to a lesser extent FLT1, FAK, and TrkA which have been 
implicated in tumorigenesis in cancers such as leukemia and breast cancer. Small cell lung 
cancer and colon cancer are the most sensitive to PF-03814735, which works by blocking 
cytokinesis and, therefore, preventing cell proliferation and creating cells that are multinucleated 
(Jani et al., 2010).  Lastly, MLN8237, also known as Alisertib, is the first oral and selective 
inhibitor of Aurora A kinase. It shows more than a 200-fold increased specificity for Aurora A 
Figure 6. Alisertib Mechanism in vitro 
Alisertib inhibits Aurora A kinase, resulting in 
mitotic entry delay. This leads to spindle 
bipolarity defects, which can lead to 
apoptosis or cell cycle reentry 
 
Retrieved from: Niu, Huifeng, Mark Manfredi, and Jeffrey 
A. Ecsedy. "Scientific Rationale Supporting the Clinical 
Development Strategy for the Investigational Aurora A 
Kinase Inhibitor Alisertib in Cancer." Frontiers in 
oncology, vol. 5, 2015, pp. 189, 
doi:10.3389/fonc.2015.00189  
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kinase than Aurora B kinase. Alisertib prevents the proliferation of cells, increases the number 
of cells in G2/M phase, and causes significant apoptosis and senescence (Figure 6) (Qi et al., 
2013).   
 
Previous work has shown that 
Alisertib, at clinically achievable 
concentrations, impairs the 
growth and survival of AML cell 
significantly more than normal 
Peripheral Blood Mononuclear 
Cells (PBMC) cells (Figure 7). 
Alisertib was also shown to 
increase the percentage of AML 
cells that experienced an 
induction of apoptosis (Kelly et 
al., 2012).  
 
Recently, a phase I trial 
conducted at Massachusetts 
General Hospital evaluated the 
safety and tolerability of Alisertib 
when combined with 
chemotherapy for patients 
diagnosed with AML. The treatment during this clinical trial involved infusions of cytarabine for 7 
days, and another chemotherapy drug, idarubicin, for 3 days. After the cytarabine infusions on 
day 7, patients were administered oral doses of Alisertib for 7 days. Overall, the researchers 
observed that Alisertib was well tolerated. The results showed that overall 86% of the patients 
that participated in the study achieved complete remission. Within the patient group, 7 out of 8 
patients that were over the age of 65 achieved a complete remission. In addition all patients that 
were diagnosed with high-risk AML achieved complete remission (Fathi et al., 2016).   
 
Despite the success of the clinical trial, in vitro studies have demonstrated that the degree of 
sensitivity of AML cell lines varied, suggesting that the unique background of individual cell 
types may be a contributing factor in the cellular response to Alisertib (Kelly et al., 2012).  
Interestingly, previous research has failed to show a direct relationship between Aurora A 
expression levels and sensitivity to Alisertib. The reason for this remains unknown. The purpose 
Figure 7. AML Cell Viability at Concentrations of Alisertib 
All AML cell lines had significantly larger decreases of cell viability 
as the concentration of Alisertib increased compared with the 
control cell line PBMC.  
 
Retrieved from: Kelly, Kevin R. et al. “Targeting Aurora A Kinase Activity with the 
Investigational Agent Alisertib Increases the Efficacy of Cytarabine through a 
FOXO-Dependent Mechanism.” International journal of cancer. Journal 
international du cancer 131.11 (2012): 2693–2703. PMC. Web. 18 Jan. 2017. 
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of this project is to explore biomarkers that indicate drug efficacy and explore the cellular 
implications of inhibiting Aurora A kinase by Alisertib.    
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3. Materials and Methods 
3.1 Subculture of Human Tissue Culture 
Table 1. AML and Control Cell Line Derivation  
(Obtained from ATCC cell lines) 
 
Cell Line Tissue Disease Patient Details Treatments Category 
RPE-1 Retina, eye None Female None 
Non-
Transformed 
PC-9 Lung Adenocarcinoma Unknown None Transformed 
SAOS-2 Bone Osteosarcoma 
Female, 11 
years old, 
Caucasian 
RTG, 
methotrexate, 
Adriamycin, 
vincristine, 
Cytoxan and 
aramycin-C 
Transformed 
K562 Bone Marrow 
Chronic 
Myelogenous 
Leukemia 
Female, 53 
years old 
None Transformed 
HL60 Peripheral Blood 
Acute 
Promyelocytic 
Leukemia 
Female, 36 
years old, 
Caucasian 
None Transformed 
KG1a Bone Marrow 
Acute 
Myelogenous 
Leukemia 
Male, 59 years 
old, Caucasian 
None Transformed 
U937 Pleura effusion 
Histiocytic 
Lymphoma 
Male, 37 years 
old, Caucasian 
None Transformed 
THP1 Peripheral Blood 
Acute Monocytic 
Leukemia 
Male, 1 year old None Transformed 
 
In the experiments and results discussed below, a variety of AML and control cell lines are 
utilized. The control cell lines include RPE-1, PC-9 and SAOS-2.  RPE-1 act as a negative 
control, as this cell line is non-cancerous and has not been reported to have any abnormal 
expression of Aurora A kinase. PC-9 and SAOS-2 both are cancerous tissues, and therefore, 
may have an overexpression of Aurora A. However, these will act as positive controls and help 
to determine cellular factors that may be specific to AML (Table 1).  
 
Each cell line was subcultured at a ratio 1:5 every 72 hours. For adherent cell lines (RPE-1, 
RPE-PLK4, PC9, and SAOS2), the media was aspirated out, and 2 mL of 1XPBS was used to 
rinse the cells.  The 1XPBS was then aspirated out and 2 mL of trypsin was added to the cells.  
The cells were left at 37C for 5 minutes. After the incubation period, 8 mL of media was added 
to the trypsinized cells. Two mL of this cell suspension was removed, placed into a new T75 
flask, and the total volume increased to 10mL with media.  All suspension cell lines (U937, 
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THP1, K562, and KG1a) were subcultured by moving 2 mL out of the current flask, transferring 
the 2mL to a new T75 flask, and bringing up the volume to 10mL with fresh media.  
3.2 Fixing and Staining AML Cells for Immunofluorescence   
Polylysine coverslip preparation 
 
Coverslips were immersed in 10% acetic acid for 10 minutes in a shaking tray. Afterwards, the 
acetic acid was removed and the coverslips were washed with water twice by shaking for 10 
minutes. Next, the coverslips were incubated in 10% polylysine (diluted in water) for 10 minutes.  
The 10% polylysine solution was removed and the coverslips were dipped briefly in water, and 
then air dried in a rack before use.  
 
Immunofluorescence  
 
In 2mL of media, 1.0 x 106 cells of each AML cell line and the RPE cells were plated. Each well 
received a polylysine coated coverslip. 24 hours after plating the cells, Alisertib was added so 
the final concentrations were 0nM (untreated), 25nM, 50nM, and 100nM. The cells were 
exposed to Alisertib for 18 hours. After exposure to Alisertib, the plates containing AML cells 
were centrifuged at 1000 rpm for 5 minutes to promote adherence of cells to the coverslip. Each 
coverslip was transferred to a dish containing 1mL ice cold methanol and was incubated at -
20ºC for 15 minutes. The plates were then centrifuged again at 1000 rpm for 5 minutes. After 
centrifugation, the methanol was removed, and coverslips were washed with 1mL of 1x PBS. 
Coverslips were then blocked in 1mL TBS/BSA for 20 minutes at room temperature.  
 
Primary antibodies were prepared by diluting dm1α (Santa Cruz Biotechnology, Reference 
Number: SC-32293) and centrin-2 (Santa Cruz Biotechnology, Reference Number: SC-27793R) 
1:1000 and 1:200, respectively, in 1mL of TBS/BSA. The coverslips were placed in a humid 
chamber and 100 μL of primary antibody was added to each coverslip for 90 minutes. The 
coverslips were washed with TBS/BSA for 5-10 minutes. Secondary antibody was prepared at a 
1:1000 dilution in DAPI/TBS. The coverslips were incubated with 100 μL of secondary antibody 
in a humid chamber in the dark for 45-60 minutes. The coverslips were then washed with 
TBS/BSA for 5-10 minutes, and then were mounted on a slide with Molecular Probe Prolong 
Gold Antifade Reagent (Reference Number: P36934).  
 
 
 
 | 18 P a g e
 
Afterwards, each slide was viewed on a Nikon Ti at the objective 60X. To view the staining, 
channels DAPI, FITC, and TxRed were used to image the DAPI, centrin-2 and dm1-alpha 
staining respectively.  
 
For this experiment, there were three biological replicates, each containing two technical 
replicates.  
3.3 Observing Alisertib Impact on Acute Myeloid Leukemia Cells 
Viability Assay  
 
The five AML cell lines (U937, HL60, THP1, KG1a, and K562) and three control cell lines (RPE, 
PC9, and SAOS2) were treated with a range of Alisertib concentrations. 100 μL of media 
containing 6,000 cells were used in each well of a 96-well plate, and 100 μL of media or media 
with Alisertib concentrations of 10nM, 25nM, 50nM, 100nM, and 250nM were added. The 
viability assay contained three technical replicates in each plate and three biological replicates 
were done for each cell line. Resistant cell lines to Alisertib, U937 and K562, as well as the 
three controls were used for additional viability assays at Alisertib concentrations of 500nM, 
750nM, 1μM, with the same volume and number of cells. 
 
After three days of exposure to Alisertib, 20 μL of Thermo Fisher Presto Blue was added to 
each well.  After 2h, the plate was read on a PerkinElmer 2030 Explorer at 600 A.  
 
For this experiment, there were three biological replicates, each containing two technical 
replicates.  
 
 
FACS Analysis 
 
2.0 x 106 cells were plated in 10 cm dishes and media was added up to 10 mL. After 24 hours, 
the cells were treated with 100 ng/mL Nocodazole and with Alisertib concentrations of 100nM 
and 250nM for 16h. For only Alisertib treatment, the cells were plated and after 18 hours, were 
treated with 100 nM or 250 nM of Alisertib for 16h. Then 10uL of Thermo Fisher BrdU was 
added to the media for 1 hour. Afterwards, the media was collected in 15mL tubes and 
centrifuged at 1000rpm for 5 minutes, and the supernatant was aspirated. The pellet was 
resuspended in 150uL of PBS, followed by the addition of 350uL of cold 100% methanol. The 
500uL solution was then collected in an Eppendorf tube and stored at -20C.  
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For analysis, the samples were spun at 800 rpm for 5 minutes, and the supernatant was 
aspirated. The pellet was washed twice in PBS, spinning and aspirating the supernatant 
between the two washes. 50 uL of 100 ug/mL ribonuclease and 200 uL of 50 ug/mL PI were 
added to each sample. The samples were run on the Accuri C6 Flow Cytometer, with a 
threshold of 50,000 events.   
 
QPCR Protocol  
 
RNA was extracted from AML cell lines using Trizol (Ambion, Life Technologies) and 
complementary DNA was synthesizes using the Superscript first-strand synthesis system 
(Applied Biosystems – Life Technologies, Austin, TX, USA). Aurora A expression was then 
analyzed using primers (Table 2). To establish target-gene expression levels, complementary 
DNA was quantified using the SYBR green kit (Applied Biosystems – Life Technologies, Austin, 
TX, USA), gene-specific primers, as well as GAPDH specific primers using relative 
quantification analysis. The copy number of the gene of interest was normalized to the copy 
number for GAPDH.   
 
Table 2. qPCR Primer Sequences 
 
G
A
P
D
H
 Forward 5’ – CCCTCTGGTGGTGGCCCCTT – 3’ 
Reverse 5’ – GGCGCCCAGACACCCAATCC – 3’ 
 
A
U
R
K
A
 Forward 5’ – TTTTGTAGGTCTCTTGGTATGTG – 3’  
Reverse 5’ – GCTGGAGAGCTTAAAATTGCAG – 3’  
 
For this experiment, there were three biological replicates, each containing two technical 
replicates.   
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 4. Results 
4.1 Characterization of AML and Control Cell Lines 
 Several research 
studies have shown 
that Aurora A kinase is 
overexpressed in a 
wide variety of human 
cancers such as breast, 
colon, and cervical 
cancers (Fu et al, 
2013). It has previously 
been demonstrated that 
AML cells frequently 
exhibit amplification or 
increased expression of 
the Aurora Kinase A 
gene (AURKA) (Kim et 
al, 2012).    
We therefore investigated Aurora A kinase levels in AML cell lines using quantitative PCR. The 
RPE-1 cell line was used as the baseline for a normal expression of Aurora A kinase. KG1a, 
HL60 and THP1 all showed comparable Aurora A kinase expression to RPE-1 cells, whereas, 
the cell line U937 had a three-fold increase over RPE-1, and K562 had an eight-fold increase 
(Figure 8). 
   
Given the well documented role for Aurora A in centriole duplication, regulation of mitotic spindle 
formation, and mitotic progression, Aurora A has been proposed to be a promising target for 
novel AML therapeutic approaches (Fu et all, 2007). However, it remains unclear to what extent 
Aurora A over-expression, or additionally, associated cellular phenotypes, may indicate a likely 
response of the patient to therapeutic approaches that inhibit Aurora A function.  
 
 
Quantitative PCR analysis of Aurora A kinase expression in AML and control 
cell lines. K562 and U937 scored had significantly higher fold expression over 
the control cell line, RPE-1.  Standard Deviation is 1 way ANOVA, P value < 
0.01 (**), P value < 0.001 (***) 
 
Figure 8. qPCR of Aurora A Expression in AML Cells over RPE-1 
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Figure 8A shows immunoflouresence images of cells 
representative of each cell line’s average centriole 
number. Figure 8B shows the scoring of each cell 
line’s centriole number  
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AML + Control Cell Line Mitotic Index 
Immunoflouresence analysis was utilized to score 
mitotic index for AML and control cell lines. All AML 
cell lines had a mitotic index comparable to RPE-1 
 
Figure 10. Centriole Number of AML and Control Cell Lines 
To begin to explore the relationship 
between Aurora A overexpression 
related phenotypes and sensitivity to 
the inhibitor Alisertib, we initially 
characterized our panel of AML cell 
lines, using immunofluorescence 
microscopy, to assess spindle 
morphology, centriole number, ,and 
mitotic index. The RPE-1 cell line was 
utilized as a negative control (Table 1). 
Consistent with previous reports, our 
control RPE cells exhibit a mitotic 
index near 1%, with >70% of 
interphase cells containing a single 
pair of centrioles (Lambrus, 2015).  
The vast majority of mitotic RPE cells 
display a bipolar spindle and two pairs 
(four) of centrioles (Lambrus, 2015).  
Immunofluorescence analysis using 
alpha tubulin and DAPI (DNA) staining 
to identify mitotic nuclei indicated that 
AML cell lines exhibit a mitotic index 
between 0.5 and 2.0%, comparable to 
the percentage scored in the RPE-1 
cell line (Figure 9). Previous research 
has shown that Aurora A 
overexpression can result in 
centrosome amplification, and lead to 
multipolar spindles and abnormal 
segregation of the chromosomes 
(Bavestias & Linardopoulos, 2015). 
However, only cell line K562, the one 
with the highest Aurora A levels, 
exhibit an increase in cells with >4 
B 
Figure 9. Mitotic Index of AML and Control Cell Lines 
A
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centrioles (Figure 10). Consistent with measured centriole number, K562 cells but not those with 
normal centriole number, also exhibit an increase in multipolar mitotic spindles (Figure 11).  
 
 
 
 
   
 
 
 
4.2 Effect of Alisertib on AML and Control Cell Lines 
To examine the susceptibility of the AML cells to mitotic arrest, and Alisertib-induced mitotic 
arrest, Fluorescence Activated Cell sorting (FACS) analysis was used to monitor DNA content 
as a readout of cell cycle progression following treatment with Alisertib alone, or Alisertib 
together with the microtubule poison Nocodazole. In figure 12A, 1.7% of PC9 cells were in 
mitosis, this percentage increased to 70.3% when treated with 250 nM of Alisertib and 100 
ng/mL Nocodazole. For HL60 cells, both the 100 nM and 250 nM treatments were able to halt 
50% of cells in mitosis. (Figure 12A). Immunofluorescence was used to score the mitotic index 
of AML cells after treatment with increasing concentrations of Alisertib. For AML cell lines K562, 
KG1a and HL60, all experienced significant increases in mitotic index at 50 and 100 nM of 
Alisertib (Figure 13). This analysis demonstrated that AML cells are responsive to conditions  
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Figure 11. Spindle Morphology of AML and Control Cell Lines Untreated 
Immunofluorescence analysis of the spindle morphology in the AML and control 
cell lines. K562 was scored to have a higher population of multipolar spindle 
poles in comparison to the control cell line. 
 
A 
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that perturb mitotic progression such 
that Alisertib treatment, either alone or 
in combination with Nocodazole, leads 
to an enrichment of cells with 
4N/mitotic DNA content.  
 
To explore the cause of this mitotic 
arrest, we performed 
immunofluorescence imaging analysis 
of mitotic structures in our AML cells 
with and without Alisertib treatment. In 
AML cells,   Aurora A kinase inhibition 
by Alisertib can induce mitotic 
assembly defects, such as monopolar 
spindle morphology (Bavestias & 
Linadopoulos, 2015). We specifically 
examined the effect of Aurora A kinase 
inhibition on monopolar spindle 
formation in AML cells. 
The control cell line, 
RPE-1, experienced a 
dose-dependent increase 
of monopolar cells with 
the number of monopolar 
cells specifically 
increasing by 47% in 
response to 100 nM  
Alisertib (Figure 14).  
Three of the AML cell 
lines, KG1a, THP1 and 
HL60 showed a 
monopolar spindle 
formation increase 
comparable to RPE-1 
 
FACS used to monitor cell cycle progression with Alisertib 
and Nocodazole (Figure 12A) or with increasing 
concentrations of Alisertib (Figure 12B). All AML cell lines 
were responsive to both treatments and halted during 
mitosis. 
Figure 12. AML and Control Cell Lines Treated with 
Nocodozale and Alisertib FACS Analysis 
Figure 13. Mitotic Index for AML Cells Treated with Alisertib 
Immunofluoresence was used to score mitotic index for AML cells 
treated with varying concentrations of Alisertib. K562, KG1a and HL60 
experienced significant increases in mitotic index at 50 and 100 nM of 
Alisertib. Standard Deviation is  1 way ANOVA: P value < 0.05 (*), P 
value < 0.01 (**), P value < 0.001 (***).   
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(Data not shown). However, in response to 100 nM Alisertib, K562 displayed a 2% monopolar 
spindle formation (Figure 14).  
 
 Cells that experience Aurora A 
inhibition, and have formed 
monopolar spindle poles will 
experience a spindle checkpoint 
mitotic arrest. This arrest is temporary 
and can promote apoptosis 
(Bavetsias & Linardopoulous, 2015). 
To study the immediate effects of 
Aurora A inhibition on cell viability, 
and the sensitivity of the cells lines to 
Alisertib, we performed viability 
assays. Viability assays use Presto 
Blue, which is initially blue in color, 
and is rapidly take up in viable cells 
and converted into a red fluorescent 
dye. The number of viable cells can 
be measured by comparing the 
change in absorbance levels. We 
used this assay to determine the 
number of viable cells after being 
treated with Alisertib for 72 hours. 
The results for each cell line were 
normalized to its untreated condition. 
The sensitivity of the cells can be 
determined by their normalized 
Relative Expression Units (REU), 
where the value of 1 implies that the 
number of viable cells is the same as 
the untreated condition. The controls 
for these assays were the RPE-1, 
SAOS2 and PC9 cell lines.  RPE-1 and SAOS2 experience significant decreases in cell viability 
 
Immunofluorescent images of  AML and control cell lines at 
untreated, 50 and 100 nM of Alisertib. The percentages 
represent the percentage of monopolar spindles observed at 
each concentration for each cell line  
Figure 14. AML and Control Cell Line Spindle Pole Formation at 
Various concentrations of Alisertib 
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at 50 nM. PC9 had decreases 
in cell viability at 100 nM and 
250 nM. HL60 had an  
increased sensitivity to 
Alisertib, as shown by the 
large reduction in cell viability 
at 10 nM. K562 and U937 had 
the lowest drug sensitivity, as 
neither of these cell lines had 
a significant decrease in cell 
viability until 250 nM (Figure 
15).  As described above, the 
K562 cell line overexpresses 
Aurora A kinase compared to 
controls and has a high 
incidence of extra 
centrosomes (Figures 9 & 
10). This cell line may exhibit 
limited sensitivity to Alisertib 
due to inability to fully inhibit 
Aurora A activity.  
Alternatively, multipolar 
spindle morphology in these 
cell lines may render them 
resistant to forming monopolar spindles, maintaining a mitotic arrest, and ultimately undergoing 
apoptosis.  To determine if high levels of Aurora A in K562 cells can be inhibited comparably to 
that In cell lines that are more responsive to Alisertib treatment, we are utilizing western blotting 
techniques to measure Aurora A levels together with  autophosphorylation (as a readout of its 
kinase activity) in each AML cell line before and after Alisertib treatment.  
 
Viability assays were used to assess cell viability in each cell line 
with concentrations of Alisertib. K562 and U937 both scored to have 
reduced drug sensitivity to Alisertib. Standard Deviation is  1 way 
ANOVA: P value < 0.05 (*), P value < 0.01 (**), P value < 0.001 (***).  
Figure 15. AML and Control Cell Lines Viability at Concentrations of 
Alisertib 
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4.3 Experimental Confirmation of Polo-Kinase 4 Overexpression to Amplify Centriole Number 
 
In a second approach, to test 
if sensitivity to Alisertib might 
be impacted by centrosome 
number, independent of 
Aurora A levels, we utilized a 
cell line system with inducible 
PLK-4 expression. Polo-like 
kinase 4 (PLK-4) is a cell 
cycle kinase involved in 
centrosome maturation. 
When overexpressed, PLK-4 
can induce centriole 
amplification by producing 
multiple procentrioles that 
adjoin to the parental 
centriole (Kleylein-Sohn et al, 
2007). This centriole 
amplification is  independent 
of increased Aurora A kinase levels. It is possible that the Alisertib sensitivity observed in the 
AML cell lines could be due centriole number and subsequent spindle morphology defects 
instead of, or in addition to increased Aurora A kinase levels. To test this, we obtained an RPE 
cell line engineered to carry a tet-regulated PLK-4 expression construct. By using this cell line, 
the specific effects of centriole amplification on drug sensitivity could be elucidated 
 
We used 2 µg/mL of doxycycline to induce PLK-4 overexpression and to induce the proliferation 
of centrioles within these cells (Figure 16). The PLK-4 plasmid is regulated by tetO, when 
doxycycline is added, it drives the expression of PLK-4. This overexpression leads to the 
amplification of centrioles (Figure 15). To monitor induction and function of PLK-4 
overexpression, immunofluorescence analysis was used to observe centriole number in normal 
and induced cells. The PLK-4 RPE cells with normal PLK-4 expression retained 2 centrioles in 
non-mitotic cells, and 4 centrioles in mitotic cells (Figure 17).  The cells that overexpress PLK-4, 
 
Figure 16A shows the PLK-4 plasmid, and its transcription is 
activated by the addition of doxycycline. Figure 16B shows the 
experimental set-up of the induction of PLK-4 overexpression in 
RPE-1 cells. Doxycycline is added to RPE-PLK-4 cells, which 
results in the overexpression of  PLK-4. This leads to the formation 
of additional procentrioles leading to the development of mature 
centrioles.  
A 
B 
Figure 16. PLK-4 Overexpression Experimental Layout 
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had an increased number of centrioles 
in both non-mitotic and mitotic cells 
(Figure 17). 60% of mitotic cells 
overexpressing PLK-4 had a 
multipolar spindle formation. This data 
confirms that the induction of PLK-4 in 
the RPE-1 PLK-4 cell line can 
successfully induce the 
overduplication of centrioles.   
4.4 Investigating Effect of Alisertib on 
Cells with PLK-4 Overexpression  
 
Overexpression of PLK-4 will lead to 
the amplification of centrioles within 
the cell (Kleylein-Sohn, 2007), and our 
results suggest that centriole 
amplification could be a factor in 
reduced Alisertib sensitivity in some 
AML cell lines. To further explore this, 
mitotic index, spindle morphology and 
cell viability were scored in cells with 
and without PLK-4 overexpression 
following 18 hours of treatment with 
increasing amounts of Alisertib. Aurora 
A inhibition can cause cells to activate 
mitotic checkpoint and sustain mitotic 
arrest (Bavetsias & Linardopoulos, 
2015), so treatment with Alisertib could 
result in an increased mitotic index. 
However, for cells with both normal and 
overexpressed PLK-4 , the mitotic index 
did not significantly increase as the 
concentrations of Alisertib increased 
 
Immunoflourescence analysis of  PLK-4 RPE-1 
cells to confirm overexpression of PLK-4 and 
centriole amplification as a result.  
Figure 17. PLK-4 Overexpression and Centriole 
Amplification Confirmation 
 
 
Mitotic index was scored in normal and overexpressed 
PLK-4 cells in 50 and 100 nM of Alisertib. Both normal and 
overexpressed PLK-4 cells showed an increased mitotic 
index as Alisertib concentrations increased.  
Figure 18. Mitotic Index of Normal and Overexpressed PLK-4 
Cells 
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(Figure 18). This could suggest that the Aurora A inhibition by Alisertib was not significant 
enough to result in increased mitotic arrest in RPE-1 PLK-4 cells.  
 
We next examined the effect of centriole amplification on monopolar spindle formation using 
Alisertib to inhibit Aurora A kinase in the RPE-1 PLK-4 cells, with or without induction of PLK-4 
overexpression. PLK-4 overexpression with increasing concentrations of Alisertib did not 
increase the percent of cells with monopolar spindles (Figure 19). However, approximately 40 – 
60% of the overexpressed PLK-4 cells had a multipolar spindle structure (Figure 19).   
 
 
Figure 19. Spindle Morphology of Normal and Overexpressed PLK-4 cells 
                                     
 
 
 In one of the analyzed AML cell lines (K562) centriole amplification and reduced sensitivity to 
Alisertib were observed. To examine the role of centriole proliferation in Alisertib sensitivity, 
without additional factors like Aurora A overexpression as seen in the two AML cell lines, the 
RPE-1 PLK-4 cell line was used. The cells with regular levels of PLK-4 expression behaved 
comparably to the RPE-1 cells in Figure 12, showing a significant decrease in cell viability at 50 
nM. In the cells with PLK-4 overexpression, there was not a significant decrease in cell survival 
until 250 nM (Figure 20). This is similar to what was observed in the K562 and U937 cell lines in 
0
20
40
60
80
100
120
Normal PLK-4 Overexpressed
PLK-4
Normal PLK-4
(1 replicate)
Overexpressed
PLK-4
Normal PLK-4 Overexpressed
PLK-4
Untreated 50 nM 100 nM
P
er
ce
n
ta
ge
 o
f 
To
ta
l C
el
ls
 
Normal vs. Overexpression of PLK-4 Spindle Polarity 
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Immunofluorescent analysis of normal and overexpressed PLK-4 on spindle 
morphology at 50 and 100 nM of Alisertib. Cells with PLK-4 overexpression 
maintained multipolar spindle morphology even at 50 and 100 nM of Alisertib.  
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(Figure 20). These results demonstrate that an increase in centriole number could be a 
contributing factor in the decreased sensitivity of Alisertib. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Viability assays were used to assess the cell viability of normal and 
overexpressed PLK-4 cells at concentrations of Alisertib. Overexpressed 
PLK-4 cells did not show a significant decrease in cell survival until 250 
nM. Standard Deviation is 1 way ANOVA: P value < 0.05 (*), P value < 
0.01 (**), P value < 0.001 (***) 
Figure 20. Normal and Overexpressed PLK-4 Cell Viability at Concentrations of 
Alisertib 
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5. Conclusions and Future Work 
 
In this study, we have utilized several methods to observe the effects of Aurora A kinase 
inhibition on AML cells and the role of centriole abundance in drug sensitivity.  After assessing 
the AML and control cells for centriole number and spindle polarity, we examined the drug 
sensitivity of each cell line to increasing concentrations of Alisertib. We observed that three cell 
lines (K562, U937 and THP1) had a reduced sensitivity to Alisertib and two of these cell lines 
(K562 and U937) also had an increased centriole number.  These results led us to question if 
centriole number was a contributing factor to drug sensitivity.  
 
From these results, we investigated the potential relationship between centriole amplification 
and drug sensitivity. Using RPE-PLK4 cells, we were able to induce centriole amplification 
within the cells, and observed cellular changes when the cells were exposed to 50 nM, 100 nM 
and 250 nM of Alisertib. We observed that cells that had an overexpression of PLK-4 continued 
to have multipolar spindle poles, even at the concentration of 100 nM. However, more replicates 
of the spindle polarity experiment will have to be completed to verify these results. In addition, 
cells with PLK-4 overexpression had a reduced Alisertib sensitivity compared to the cells with 
normal levels of PLK-4.  The cells without PLK-4 overexpression experienced a decrease in cell 
survival at 50 nM Alisertib, whereas the cells viability was not significantly affected in cells 
overexpressing PLK-4 until 250 nM. At Alisertib concentrations higher than 250 nM, both cell 
types were sensitive to the drug and cell survival decreased significantly. From these 
experiments, we conclude that centriole abundance may play a role in reduced drug sensitivity. 
 
While centriole number may play a role in Alisertib sensitivity and monopolar spindle formation, 
the mechanism of this action and other cellular factors that may contribute were not 
investigated. Therefore, in future projects, it could be taken into consideration to overexpress 
Aurora A expression in RPE or non-AML cell lines and observe the effects on the cell’s 
sensitivity to Alisertib. This would help to decipher if Aurora A overexpression has a significant 
impact on the monopolar spindle pole formation or the sensitivity of the cells to Alisertib. Loss of 
PLK-4 has been shown to prevent centriole duplication (Holland et al., 2012) Therefore, to 
further test the impact of centrosome number on Alisertib sensitivity, it would also be interesting 
to reduce the expression of PLK-4 in K562 (the cell line with an increase in centriole number), to 
observe the impact of reduced centriole number in these cell lines. This would provide additional 
insight into the relationship of centriole abundance and drug sensitivity.  
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To further understand the relevance of centriole abundance and drug sensitivity, in vivo models 
could be utilized to further assess what factors impact the effectiveness of Alisertib. For 
example, a cell line with centriole abundance such as K562 could be injected into mice, and 
another cell line that maintains normal centriole number, such as KG1a could be injected into 
another set of mice. Each set of mice would be divided into subgroups, and each subgroup 
would receive different concentrations of Alisertib. This experiment would be used to support 
previous experiments and also explore the potential effects of centriole amplifications in tumor 
growth and treatment in living models.  If centriole amplification is found to be a cellular factor in 
reduced drug sensitivity in the in vivo model, another experiment could be completed with mice 
being injected with K562, followed by a treatment that reduces the expression of PLK-4, to 
reduce centriole number. During the experiment, these mice would also be treated with a single 
concentration of Alisertib. The tumor growth would be observed throughout the course of the 
experiment, to determine if drug sensitivity can be increased when centriole number is 
decreased. 
 
These results could lead to further patient studies, where blood samples from each patient are 
taken and their cellular structure is analyzed. If their cells show signs of centriole abundance, 
physicians may instruct the patients to use higher dosing or even a treatment different from 
Alisertib or use a combination of therapies to target the leukemic cells in addition to Alisertib. 
This would be an initial step to creating patient profile that would indicate drug efficacy based on 
cellular structure.  
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